Highest-materiality recent filing
Aspira Women's Health enters $1.05M subordinated loan with Agile Lending, matures Jan 2027
Principal $1,050,000; interest charges $441,000; maturity January 26, 2027.
Aspira Women's Health finalizes CEO Buhle separation: $200K severance, 64,583 options accelerated
Cash severance $200,000 (6 months base salary) payable in installments; prorated $4,615.38 on July 15 payroll if signed by June 29.
Aspira Women's Health CEO Michael Buhle departs; Chairman John Fraser named interim CEO
Michael Buhle ceased as CEO effective June 17, 2026; no disagreement with company operations.
Aspira Women's Health annual meeting results: all proposals approved
All six director nominees elected with ~95% of votes cast in favor (excluding broker non-votes).
Aspira Women's Health raises ~$1.5M in private placement of common stock and warrants
Issued 3.3M shares and warrants to purchase up to 4.455M shares at $0.45 per unit.
Aspira Women's Health enters collaboration with Cleveland Clinic for AI-powered diagnostics
Partnering fee of $125,000; $50,000 due within 30 days, then $25,000 on each of first three anniversaries.
Aspira Women's Health appoints John Strahley as CFO; Brian Hungerford departs
Brian Hungerford's consulting agreement terminated at his request effective April 26, 2026, for personal reasons.
Aspira enters lab services pact with Mayo Clinic for Ova1Plus and OvaWatch tests
Agreement effective Dec 16, 2025; Mayo will list Aspira’s Ova1Plus and OvaWatch in its test catalog.
Aspira Women's Health enters $1.05M subordinated loan with Agile Lending, maturing Aug 2026
Principal of $1,050,000 plus $441,000 interest due; matures August 26, 2026.
Aspira Women's Health publishes investor presentation on its website on December 29, 2025
No specific financial or strategic updates identifiable from the limited presentation text provided.
Aspira Women's Health enters $10M equity line with Lincoln Park Capital
Lincoln Park committed to purchase up to $10M of Aspira common stock at company's discretion over 24 months.
Aspira Women's Health signs 5-year lab services pact with Mayo Clinic
Aspira will provide Ova1Plus and OvaWatch tests to Mayo on a non-exclusive, as-requested basis for clinical purposes.
Aspira Women's Health Q3 revenue flat at $2.3M; gross margin expands to 64.1%
Nine-month gross profit $4.5M (+12.2% YoY); margin 64.1% vs 58.4%.
Aspira Women's Health amends 8-K to correct warrant termination date
Filing corrects termination date in Series A Common Stock Warrants disclosed on Sept 25, 2025.
Aspira Women's Health upgrades to OTCQX from OTCQB effective Oct 14, 2025
Upgraded from OTCQB Venture Market to OTCQX Best Market on October 14, 2025.
Amendment requires Aspira to file Form S-1 by Sept 30, 2025 to register shares and warrant shares.
Aspira Women's Health raises $3.06M in private placement at $0.45/unit, issues 6.55M shares
Gross proceeds $2.95M from sale of 6.55M shares and 4.91M warrants at $0.45/unit; plus $112.5K from exercise of 450K warrants.
Aspira Women's Health appoints Brian Hungerford as CFO, $300K salary, 100K options
Brian Hungerford appointed CFO and Principal Accounting Officer, effective September 2, 2025, replacing Julie Carrillo.
Aspira Women's Health Q2 revenue stable at $2.4M; H1 gross margin improves to 66.1%
Q2 product revenue $2.404M vs $2.423M YoY; commercial portfolio AUP up 12%.
Aspira Women's Health appoints Jane Pine Wood to board effective July 11, 2025
Jane Pine Wood appointed as director, effective July 11, 2025.
Aspira Women's Health says ARPA-H terminated $10M ENDOinform contract after receiving $3.5M
ARPA-H terminated $10M contract for ENDOinform test on June 9, 2025, citing unmet Milestone 3 specs.
Aspira Women's Health 2025 annual meeting results: all proposals approved
All six director nominees elected with over 96% of votes cast in favor.
Aspira Q1 revenue up 5.9% to $2.28M; gross margin 68.5%, cash burn reduced 30%
Revenue $2.28M vs $2.15M YoY (+5.9%), driven by select price increases and 94% jump in sales per FTE.
Aspira Women's Health receives Nasdaq delisting notice for failure to meet equity minimum
Received written notice on April 15, 2025 that Nasdaq Hearings Panel determined to delist shares due to non-compliance with Listing Rule 5550(b)(1).
Aspira Women's Health raises up to $2M via discounted equity; appoints three new directors
Equity purchase agreement with Triton Funds for up to $2M; first tranche 354,988 shares for $25,000.
Aspira Women's Health enters new CEO employment agreement; $400k salary, 100k option grant
Base salary $400,000 with target bonus up to 50% based on corporate goals.
Aspira Women's Health amends bylaws, reduces stockholder meeting quorum to one-third
Board approved amendment to Bylaws on March 28, 2025, reducing quorum to 33.33% of outstanding shares.
Aspira Women's Health Q4 product revenue up 9.5% to $2.3M; FY revenue flat at $9.2M
Q4 product revenue $2.3M (+9.5% YoY); OvaSuite tests ~6,004 (+6.1%); AUP $391 (+4.3%); gross margin 63.4% (+6.2 ppts).
Aspira Women’s Health VP of Finance James Crawford resigns effective April 4, 2025
James Crawford informed CEO Mike Buhle of his resignation as VP of Finance on March 21, 2025.
Director Celeste Fralick resigns from Aspira Women's Health board
Celeste Fralick resigned as director for personal reasons, effective March 31, 2025.
Aspira Women's Health closes $1.37M private placement of convertible notes
Issued $1.37M principal amount of Senior Secured Convertible Notes due March 2030.
Received Nasdaq notice Feb 11, 2025 for violating Rule 5635(c) by issuing shares/warrants below market value without shareholder approval.
Aspira Women's Health President resigns; appoints new director Ellen Beausang
Dr. Sandra Milligan resigns as President effective Feb 21, 2025, for personal reasons.
Aspira Women's Health appoints Michael Buhle as CEO, James Crawford as VP of Finance
Michael Buhle appointed CEO, adds role to current Chief Commercial Officer duties; effective Jan 28, 2025.
Aspira Women's Health files 8-K with investor presentation; no specifics in text
Investor presentation furnished as Exhibit 99.1 for January 13, 2025 meeting.
Aspira Women's Health interim CFO John Kallassy resigns; CEO becomes principal accounting officer
John Kallassy resigned as Interim CFO effective January 10, 2025, for personal reasons.
Aspira Women's Health receives Nasdaq delisting notice for MVLS non-compliance
Notice received Dec 31, 2024; company failed to regain $35M MVLS requirement by Dec 30, 2024 deadline.
Aspira Women's Health CEO Sandford steps down; Dr. Milligan interim CEO
CEO Nicole Sandford departs immediately for family health matter; remains as consultant for transition.
Aspira Women's Health Q3 rev $2.3M, cash burn $2.9M, reaffirms FY 2024 cash guidance
Q3 OvaSuite revenue $2.3M (+2% YoY); test volume 6,001 units (+4% YoY).
Aspira Women's Health presents pipeline status overview; no specific data in filing
Slide deck provided on October 29, 2024 covers product pipeline but full content is not included in the 8-K.
Aspira Women's Health awarded $10M ARPA-H grant for endometriosis blood test
Selected by ARPA-H for Sprint for Women's Health; $10M funding over two years to develop ENDOinform blood test for endometriosis.
Aspira Women's Health gets $10M ARPA-H award for endometriosis blood test
Selected by ARPA-H for $10 million in milestone-based funding over two years to develop EndoMDx blood test for endometriosis.
Aspira Women's Health receives Nasdaq delisting notice for bid price below $1.00
Received Nasdaq notice on Oct 17, 2024 for non-compliance with minimum bid price ($1.00) for 30 consecutive business days.
Slide deck made available under Item 7.01 Regulation FD Disclosure.
Aspira Women's Health Q2 revenue $2.4M; cuts FY cash guidance to $13-14.5M
Q2 product revenue $2.4M vs $2.5M YoY; OvaSuite volume 6,471 units (+3%).
ATM agreement with H.C. Wainwright to sell up to $4,450,000 of common stock from time to time.
Holder exercises warrants for 1,711,111 shares at reduced $1.25 (down from $4.13) for $2.14M gross proceeds.
Aspira Women's Health appoints John Ragard to Board of Directors
John Ragard appointed to board effective July 25, 2024; designated by stockholder Jack W. Schuler.
Aspira Women's Health receives Nasdaq deficiency notice for market value below $35M
Nasdaq notified AWH that MVLS was below $35M minimum for 30 consecutive business days.
Aspira Women's Health announces $1.935M private placement of 1.26M shares and warrants
Gross proceeds ~$1.935M from sale of 1,264,739 shares and accompanying warrants at $1.53 per unit.
Michael Buhle ceased serving as the Company’s Chief Executive Officer effective June 17, 2026
appointed John (Jack) Fraser as Interim Chief Executive Officer
Effective June 17, 2026, the board of directors (the “Board”) of the Company appointed John Fraser, the Company’s current Chairman of the Board, to serve as its Interim Chief Executive Officer while a search of internal and external candidates is conducted.
On June 17, 2026, Michael Buhle ceased serving as Chief Executive Officer of Aspira Women's Health Inc. (the "Company").
On April 26, 2026, the consulting agreement between the Company and Hungerford Consulting LLC, under which Brian Hungerford had served as Chief Financial Officer, terminated at the request of Hungerford Consulting LLC.
On April 26, 2026, Aspira Women's Health, Inc. (the "Company") appointed John Strahley as Chief Financial Officer and Chief Accounting Officer of the Company, effective April 27, 2026.
On April 6, 2025, the Board appointed John Fraser and Cynthia Hundorfean as directors of the Company.
On April 6, 2025, the Board appointed John Fraser and Cynthia Hundorfean as directors of the Company.
On April 2, 2025, the Board (the “Board”) of Directors of the Company appointed Jeffrey Cohen, M.D. as a director of the Company.
On April 4, 2025, the Board appointed Julie Carrillo, the Company’s Corporate Controller, to act as the Principal Accounting Officer of the Company on an interim basis.
On March 21, 2025, James Crawford informed Mike Buhle, the Chief Executive Officer of Aspira Women’s Health Inc. (the “Company”) that he was resigning as VP of Finance of the Company, for personal reasons, effective April 4, 2025.
On March 15, 2025, Celeste Fralick informed the Board of Directors of Aspira Women’s Health Inc. (the “Company”) that she was resigning as a director of the Company, for personal reasons, effective March 31, 2025.
Max materiality 0.90 · Median 0.60 · Most common event other_material